Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

FLAVCAN Innovative Flavonoid-based Nanoparticles (Flav-NPs) to Fight Against Colorectal Cancer (FLAVCAN)

Coordinator
Academisch Ziekenhuis Groningen, Netherlands
Runs
1 September 2025 to 31 August 2027
Status
Running
EU funding
€233k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101202066

What the project is doing

In the project's own words, from its summary on CORDIS.

Colorectal cancer is among the most lethal and prevalent malignancies in the world. Current treatment has limitations, such as adverse effects, drug resistance, metastasis, and recidivism. Flavonoids such as Apigenin, Epigallocatechin-3-gallate, and Quercetin have demonstrated anticancer effects and alternatives for new treatments. Flavonoids can suppress tumor growth, induce apoptosis, inhibit angiogenesis, and modulate cellular signaling pathways in development and progression.

Multiple flavonoids administrated simultaneously potentially enhance their biological activities, improving the local effect and instigating a synergistic inhibitory effect on cancer cell viability, increasing apoptosis, decreasing proliferation, and causing the arrest of the chemoresistant cells. Flavonoids are challenging to use orally for therapeutic purposes due to their molecular instability and insufficient delivery to the distal portions of the intestine.

This project uses a microfluidic platform to identify a potent flavonoid combinatory nanoformulation-based polysaccharide (cellulose derivates) for oral administration. Flav-NPs can enhance chemical stability, accurately control the release of flavonoids, and potentially overcome digestion factors. Flav-NPs can impact multidimensional mechanisms of anticancer action to more effective therapeutic, reduced cellular proliferation, and invasiveness at different cancer stages.

Pre-clinical methodologies will be applied to characterize, and stability in vitro digestion will be evaluated. Spheroid and organoid models will determine cell viability and anticancer efficacy. A gut-on-a-chip model will also be developed to observe the effects of Flav-NPs in a simulated intestinal microenvironment tumor. The simplicity of manufacturing and the feasibility of large-scale production of the supplement and nutraceuticals indicate that the proposal can be applied clinically, promoting European scientific excellence and improving my research career.

Topics

Who is involved

OrganisationCityCountryRole
Academisch Ziekenhuis GroningenGroningenNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI